Literature DB >> 35057911

Lifetime Risk of Heart Failure Among Participants in the Framingham Study.

Ramachandran S Vasan1, Danielle M Enserro2, Alexa S Beiser3, Vanessa Xanthakis4.   

Abstract

BACKGROUND: The residual lifetime risk (RLR) of developing heart failure (HF) may have changed over time because of the increasing population burden of hypertension, obesity, and diabetes; greater survival after myocardial infarction; and a greater lifespan.
OBJECTIVES: The authors assessed changes in the RLR for HF in two 25-year epochs (1965-1989 and 1990-2014).
METHODS: We compared the RLR of HF at age 50 years (adjusting for competing risk of death) in the 2 epochs in Framingham Study participants overall and in the following strata: sex, body mass index, blood pressure, and diabetes.
RESULTS: Mean life expectancy increased from 75.9 to 82.1 years in women and 72.5 to 78.1 years in men. We observed 624 HF events over 111,351 person-observations in epoch 1, and 875 HF events over 128,903 person-observations in epoch 2. The mean age at onset of HF increased across the epochs by 6.6 years (women) to 7.2 years (men). The RLR of HF at age 50 years increased across epochs from 18.86% to 22.55% (absolute increase 3.69; 95% CI: 0.90-6.49; P = 0.01) in women, and from 19.19% to 25.25% (absolute increase 6.06; 95% CI: 3.08-9.04; P < 0.001) in men. The increase in RLR of HF in the second epoch was consistent across strata with excess body mass index or higher blood pressure (relative increase of 28%-47%) and in participants without prior myocardial infarction (relative increase of 23%).
CONCLUSIONS: The RLR of HF has increased in our community-based sample of White individuals over the last 5 decades, possibly caused by an increase in life expectancy.
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cohort studies; epidemiology; heart failure; lifetime risk; period effects

Mesh:

Year:  2022        PMID: 35057911      PMCID: PMC8820638          DOI: 10.1016/j.jacc.2021.10.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  38 in total

1.  Lifetime risks of cardiovascular disease.

Authors:  Jarett D Berry; Alan Dyer; Xuan Cai; Daniel B Garside; Hongyan Ning; Avis Thomas; Philip Greenland; Linda Van Horn; Russell P Tracy; Donald M Lloyd-Jones
Journal:  N Engl J Med       Date:  2012-01-26       Impact factor: 91.245

2.  Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic.

Authors:  Youfa Wang; May A Beydoun; Jungwon Min; Hong Xue; Leonard A Kaminsky; Lawrence J Cheskin
Journal:  Int J Epidemiol       Date:  2020-06-01       Impact factor: 7.196

3.  Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences.

Authors:  Ann Marie Navar; Tracy Y Wang; Xiaojuan Mi; Jennifer G Robinson; Salim S Virani; Veronique L Roger; Peter W F Wilson; Anne C Goldberg; Eric D Peterson
Journal:  JAMA Cardiol       Date:  2018-12-01       Impact factor: 14.676

4.  Computing estimates of incidence, including lifetime risk: Alzheimer's disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro.

Authors:  A Beiser; R B D'Agostino; S Seshadri; L M Sullivan; P A Wolf
Journal:  Stat Med       Date:  2000 Jun 15-30       Impact factor: 2.373

5.  Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon
Journal:  Circ Heart Fail       Date:  2013-04-24       Impact factor: 8.790

6.  Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study.

Authors:  Gysèle S Bleumink; Anneke M Knetsch; Miriam C J M Sturkenboom; Sabine M J M Straus; Albert Hofman; Jaap W Deckers; Jacqueline C M Witteman; Bruno H Ch Stricker
Journal:  Eur Heart J       Date:  2004-09       Impact factor: 29.983

7.  Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology.

Authors:  Connie W Tsao; Ramachandran S Vasan
Journal:  Int J Epidemiol       Date:  2015-12       Impact factor: 7.196

8.  Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.

Authors:  Salim S Virani; Alvaro Alonso; Hugo J Aparicio; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Susan Cheng; Francesca N Delling; Mitchell S V Elkind; Kelly R Evenson; Jane F Ferguson; Deepak K Gupta; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Chong D Lee; Tené T Lewis; Junxiu Liu; Matthew Shane Loop; Pamela L Lutsey; Jun Ma; Jason Mackey; Seth S Martin; David B Matchar; Michael E Mussolino; Sankar D Navaneethan; Amanda Marma Perak; Gregory A Roth; Zainab Samad; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Andrew Stokes; Lisa B VanWagner; Nae-Yuh Wang; Connie W Tsao
Journal:  Circulation       Date:  2021-01-27       Impact factor: 29.690

9.  Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017.

Authors:  Nicola Luigi Bragazzi; Wen Zhong; Jingxian Shu; Arsalan Abu Much; Dor Lotan; Avishay Grupper; Arwa Younis; Haijiang Dai
Journal:  Eur J Prev Cardiol       Date:  2021-12-29       Impact factor: 7.804

10.  Refocusing on the Primary Prevention of Heart Failure.

Authors:  Lua A Jafari; Rachel M Suen; Sadiya S Khan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2020-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.